Literature DB >> 25895608

A price to pay for tumor regression.

Rene Bernards1.   

Abstract

Killing cancer cells can have undesired side effects. Upon drug treatment, drug-sensitive cancer cells secrete an array of growth factors that stimulate the proliferation and dissemination of drug-resistant cells in the population.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25895608      PMCID： PMC4493272          DOI： 10.1038/cr.2015.44

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  8 in total

Review 1.  Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

Authors:  Chong Sun; René Bernards
Journal:  Trends Biochem Sci       Date:  2014-09-16       Impact factor: 13.807

Review 2.  Metastatic tumors to postextraction sites.

Authors:  A Hirshberg; P Leibovich; I Horowitz; A Buchner
Journal:  J Oral Maxillofac Surg       Date:  1993-12       Impact factor: 1.895

3.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

4.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Authors:  Christophe J Desmet; Tristan Gallenne; Alexandre Prieur; Fabien Reyal; Nils L Visser; Ben S Wittner; Marjon A Smit; Thomas R Geiger; Jamila Laoukili; Sedef Iskit; Boris Rodenko; Wilbert Zwart; Bastiaan Evers; Hugo Horlings; Abderrahrim Ajouaou; John Zevenhoven; Martin van Vliet; Sridhar Ramaswamy; Lodewyk F A Wessels; Daniel S Peeper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-12       Impact factor: 11.205

5.  Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Liesbeth C W Vredeveld; Sirith Douma; Remco van Doorn; Christophe J Desmet; Lucien A Aarden; Wolter J Mooi; Daniel S Peeper
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

6.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

7.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

Review 8.  Resistance to targeted cancer drugs through hepatocyte growth factor signaling.

Authors:  Guus J J E Heynen; Aldona Fonfara; René Bernards
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534
  8 in total
  1 in total

1.  Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.

Authors:  Eszter Molnár; Tamás Garay; Marco Donia; Marcell Baranyi; Dominika Rittler; Walter Berger; József Tímár; Michael Grusch; Balázs Hegedűs
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.